Why Neogen’s 3m food safety integration failure triggered a class action and reshaped investor sentiment in diagnostics

Neogen Corporation (NASDAQ: NEOG), a leading American food safety diagnostics provider, is facing a pivotal legal and financial test after Grant & Eisenhofer P.A. filed a class action lawsuit alleging that the diagnostics company misled investors about the troubled integration of 3M Corporation’s Food Safety Division. The lawsuit, filed in the United States District Court for the Western District of Michigan, covers all purchasers of Neogen common stock from January 5, 2023, through June 3, 2025, and accuses Neogen, Chief Executive Officer John Adent, and Chief Operating and Financial Officer David Naemura of making materially false and misleading statements regarding the operational and financial progress of the $5.3 billion acquisition.

The legal action marks a significant turning point for Neogen, which has been a key player in global food and animal safety diagnostics for over four decades. Historically, Neogen’s growth strategy has relied heavily on acquisitions, strengthening its diagnostics portfolio with veterinary pharmaceuticals, testing kits for food contaminants, and animal health products. However, the 3M Food Safety Division deal, originally celebrated as a transformative acquisition, is now under scrutiny as one of the most challenging integrations in the food diagnostics industry in recent years.

What are the detailed investor allegations in the class action lawsuit and how did the 3M integration disrupt Neogen’s financial performance and guidance?

The lawsuit alleges that Neogen violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by issuing public statements that painted an overly optimistic picture of the integration process while failing to disclose internal control weaknesses and operational inefficiencies. Institutional investors argue that the diagnostics company understated the financial impact of its integration issues and delayed critical disclosures until investor confidence began eroding.

The timeline of disclosures paints a troubling picture. On January 10, 2025, Neogen announced a $461 million non-cash goodwill impairment charge tied directly to the 3M acquisition. At the same time, the diagnostics company slashed its full-year FY25 revenue and EBITDA guidance, citing operational challenges. GAAP net income for the second quarter turned sharply negative, triggering a 5% decline in the stock to $12.36 per share.

This was followed by further negative revelations on April 9, 2025. Neogen reported quarterly revenue of $221 million, a 3.4% decline year-over-year, attributing the downturn to ongoing integration difficulties. The company again lowered FY25 guidance and disclosed that capital expenditures for FY25 were expected to surge to $100 million due to accelerated integration spending and weaker adjusted EBITDA. Adding to investor anxiety, Neogen announced that CEO John Adent would be stepping down, sparking a steep 28% stock sell-off, with shares dropping to $5.02 on unusually high trading volume of 47 million shares.

The downward spiral continued into the following quarter. On June 4, 2025, Neogen warned that its EBITDA margin was expected to fall into the “high teens,” a sharp decline from the previous quarter’s 22%. The announcement prompted another 17% slide in share price, with the stock closing at $4.96, marking a more than 60% cumulative drop from its pre-disclosure valuation.

Why are analysts viewing the Neogen lawsuit as a watershed moment for food diagnostics M&A strategies and governance transparency?

The lawsuit is being closely monitored by institutional investors and market watchers as a test case for disclosure practices in high-value mergers and acquisitions within the food diagnostics sector. Analysts highlight that Neogen’s case underscores the operational and financial risks associated with large-scale integrations, particularly in highly regulated industries where compliance, reporting accuracy, and supply chain integrity are critical.

Investor sentiment has shifted markedly since the initial integration announcements. Early enthusiasm for Neogen’s acquisition of 3M’s Food Safety Division was based on expectations of significant revenue synergies and global market expansion. However, institutional investors now point to Neogen’s struggle to harmonize reporting systems, standardize operational workflows, and maintain consistent quality assurance as a cautionary example for other diagnostics providers pursuing inorganic growth.

Furthermore, analysts suggest that this lawsuit could push regulators and investors to demand stricter M&A disclosure practices. There is growing consensus among institutional stakeholders that more conservative guidance and transparent reporting during post-acquisition transitions will become essential to maintain investor trust.

The broader food diagnostics market has seen an acceleration of acquisitions over the past five years, driven by increasing demand for food safety testing amid stricter global regulations. Neogen’s integration challenges could act as a turning point, compelling companies in this space to reassess aggressive acquisition strategies in favor of slower, more deliberate expansion models.

How might the class action lawsuit reshape Neogen’s operational strategy and what are the broader implications for investor sentiment in food safety diagnostics?

If the court certifies the class and rules in favor of investors, Neogen could face significant financial liabilities, including potential damages or settlement costs. Given its already weakened financial position—characterized by reduced EBITDA margins, lower revenue guidance, and heightened capital expenditure requirements—such an outcome could limit the diagnostics provider’s ability to pursue further strategic acquisitions in the near term.

For Neogen, restoring investor confidence will likely require a strategic reset. Analysts expect the food diagnostics provider to focus on stabilizing its core operations, improving internal financial controls, and enhancing transparency around integration progress. Neogen may also consider revising its capital allocation strategy, slowing the pace of inorganic expansion to strengthen operational efficiency before pursuing new deals.

The lawsuit also has wider implications for investor sentiment in the food safety diagnostics sector. Mid-cap diagnostics providers that rely heavily on M&A-driven growth may face increased investor skepticism, with institutional stakeholders placing greater emphasis on financial discipline, regulatory compliance, and transparent reporting. In the longer term, this shift in sentiment could reshape how companies approach acquisitions, pushing the sector toward more risk-averse and compliance-focused expansion strategies.